Aled Edwards

Last updated

Aled Morgan Edwards OC [1] (born June 1, 1962) is the founder and Chief Executive of the Structural Genomics Consortium, a charitable public-private partnership. He is Professor of Medical Genetics and Medical Biophysics at the University of Toronto, Visiting Professor of Chemical Biology at the University of Oxford, and Adjunct Professor at McGill University.

Contents

Early life

Born in Holyhead, Wales, Edwards moved to Canada in 1965 with his parents Undeg and Iwan Edwards, a choral conductor who was awarded the Order of Canada in 1995 for his contributions to Canadian music. [2]

Education

Edwards earned his bachelor's degree (1983) and his Ph.D. (1988) in biochemistry from McGill University supervised by Peter Braun.  He carried out post-doctoral studies at Stanford University in the laboratory of Roger Kornberg, where he first crystallized RNA polymerase II, [3] [4] [5] [6] a structure for which Kornberg was awarded the Nobel Prize in Chemistry in 2006.

Research contributions

From 1992 to 1997, while a professor at McMaster University, Edwards became interested in developing structural biology methods and was among the first to use mass spectrometry to identify regions of proteins prone to crystallization. [7]   He used this technique to facilitate the crystallography of key proteins involved in DNA replication and repair [8] [9] [10] before becoming interested in applying this and other methods to carry out structural biology on a proteome scale.

In 1997, now at the University of Toronto, Edwards, together with his colleague Cheryl Arrowsmith, collaborated to launch one of the first projects in structural genomics, and soon published one of the papers that defined this new field. [11] As a central player in the Protein Structure Initiative, their Toronto team contributed to more than a thousand new microbial protein structures over the next decade, developed new crystallization methods, [12] [13] and used structural methods to de-orphanize several nuclear receptors [14] [15] and study ion transport across membranes. [16]

As of 2019, Edwards has co-contributed more datasets to the Protein Data Bank than any other scientist. [17]

Business activities

In the late 1990s, Edwards co-founded and served as CEO of Borealis Biosciences and Chalon Biotech, which he merged to form Affinium Pharmaceuticals, a Toronto-based company. Affinium developed afabicin, a novel narrow-spectrum antibiotic that is now in clinical development at DebioPharm.  Several other companies have been spun out of his research programs, including Harbinger Biotechnology and Engineering, which was acquired by Epiphyte3, and 1DegreeBio, which was acquired by LabX Media Group.  

More recently, Edwards founded M4K Pharma, a company that is developing a brain-penetrant drug targeting the ALK2 kinase, in order to treat children with incurable diffuse-intrinsic pontine glioma (DIPG).  The novel open science business model [18] being developed by M4K Pharma allows its science to be disclosed on an ongoing basis, and for any approved drug to be priced affordably. Edwards serves on the Board of the Agora Open Science Trust.

Open science and science policy

Open Science

Edwards is considered one of the pioneers of open science, [19] particularly as it applied to biomedicine and drug discovery.  Since 2003, all human protein structural information derived from the SGC has been placed into the public domain, prior to publication and without restriction on use.  In 2007, he, together with Richard Gold, created the SGC Open Science Principles, under which the SGC became the first biomedical research organization to adopt open science principles that mandated sharing and eschewed patenting on any activity, including novel chemistry. In 2016, Edwards both spearheaded the Open Lab Notebook initiative, which now comprises over 20 scientists sharing their experiments as they are done, as well as collaborated with Guy Rouleau at the Montreal Neurological Institute (The Neuro) to create the concept of an open research institute. That collaboration led to the formation of the Tanenbaum Open Science Institute, [20] and to the broader institutional commitment of The Neuro to open science. In 2017, Edwards and colleagues conceptualized an open trust mechanism to share research reagents, [21] and the SGC has been using this mechanism since. Edwards also helped launch YCharOS Inc., an open science antibody characterization agency. In 2018, Edwards, Max Morgan and Owen Roberts launched the world’s first open science drug discovery company, M4K (Meds for Kids) Pharma, and developed a business model that is consistent with open science and affordable pricing. In 2019, Morgan and Edwards launched M4ND Pharma, to tackle neurological diseases using open drug discovery approaches.  For his leadership role in promoting open access drug discovery, Edwards was named a Senior Ashoka Fellow in 2015. [22]

Science and innovation policy

On the 10th anniversary of the publication of the draft sequence of the human genome, Edwards and colleagues were asked for their perspective. Their “Roads not Taken” paper, [23] which quantified the “under-studied” parts of the human genome, has led to a number of funding initiatives, including the Illuminating the Druggable Genome initiative [24] at the NIH, and presaged a number of studies that examine the unintended consequences of the peer-review system. [25]

Edwards is a champion of science reproducibility, focusing considerable attention on the quality of research reagents [26] and the need for transparent standards. 

Edwards has also contributed to science communication; he served as the scientific advisor for the Gemini Award-winning television series ReGenesis.

Awards

Dr Edwards was recently named as an Officer of the Order of Canada for “advancing Canada’s global reputation as a leader in open science research by founding the groundbreaking Structural Genomics Consortium.”

Personal

Edwards has been married to Elizabeth Edwards since 1985, and they have three children and four grandchildren.  Elizabeth is director of BioZone and Professor of Chemical Engineering and Applied Chemistry at the University of Toronto, and winner of Canada’s 2016 Killam Prize for Engineering, among other awards.  She is the daughter of Leonhard and Jeanne Wolfe, who was awarded the Order of Canada in 2009 for her contributions to Canadian planning. [27] Aled’s brother, Owain Edwards, is an entomologist at CSIRO in Australia. [28]

Related Research Articles

<span class="mw-page-title-main">Robert G. Roeder</span>

Robert G. Roeder is an American biochemist. He is known as a pioneer scientist in eukaryotic transcription. He discovered three distinct nuclear RNA polymerases in 1969 and characterized many proteins involved in the regulation of transcription, including basic transcription factors and the first mammalian gene-specific activator over five decades of research. He is the recipient of the Gairdner Foundation International Award in 2000, the Albert Lasker Award for Basic Medical Research in 2003, and the Kyoto Prize in 2021. He currently serves as Arnold and Mabel Beckman Professor and Head of the Laboratory of Biochemical and Molecular Biology at The Rockefeller University.

Tom Maniatis, is an American professor of molecular and cellular biology. He is a professor at Columbia University, and serves as the Scientific Director and CEO of the New York Genome Center.

<span class="mw-page-title-main">DNA polymerase II</span>

DNA polymerase II is a prokaryotic DNA-dependent DNA polymerase encoded by the PolB gene.

Patrick Cramer is a German chemist, structural biologist, and molecular systems biologist. In 2020, he was honoured to be an international member of the National Academy of Sciences. He became president of the Max Planck Society in June 2023.

Gene structure is the organisation of specialised sequence elements within a gene. Genes contain most of the information necessary for living cells to survive and reproduce. In most organisms, genes are made of DNA, where the particular DNA sequence determines the function of the gene. A gene is transcribed (copied) from DNA into RNA, which can either be non-coding (ncRNA) with a direct function, or an intermediate messenger (mRNA) that is then translated into protein. Each of these steps is controlled by specific sequence elements, or regions, within the gene. Every gene, therefore, requires multiple sequence elements to be functional. This includes the sequence that actually encodes the functional protein or ncRNA, as well as multiple regulatory sequence regions. These regions may be as short as a few base pairs, up to many thousands of base pairs long.

The Structural Genomics Consortium (SGC) is a public-private-partnership focusing on elucidating the functions and disease relevance of all proteins encoded by the human genome, with an emphasis on those that are relatively understudied. The SGC places all its research output into the public domain without restriction and does not file for patents and continues to promote open science. Two recent publications revisit the case for open science. Founded in 2003, and modelled after the Single Nucleotide Polymorphism Database (dbSNP) Consortium, the SGC is a charitable company whose Members comprise organizations that contribute over $5,4M Euros to the SGC over a five-year period. The Board has one representative from each Member and an independent Chair, who serves one 5-year term. The current Chair is Anke Müller-Fahrnow (Germany), and previous Chairs have been Michael Morgan (U.K.), Wayne Hendrickson (U.S.A.), Markus Gruetter (Switzerland) and Tetsuyuki Maruyama (Japan). The founding and current CEO is Aled Edwards (Canada). The founding Members of the SGC Company were the Canadian Institutes of Health Research, Genome Canada, the Ontario Research Fund, GlaxoSmithKline and Wellcome Trust. The current Members comprise Bayer Pharma AG, Bristol Myers Squibb, Boehringer Ingelheim, the Eshelman Institute for Innovation, Genentech, Genome Canada, Janssen, Merck KGaA, Pfizer, and Takeda.

<span class="mw-page-title-main">Eva Nogales</span> Biophysicist, professor

Eva Nogales is a Spanish-American biophysicist at the Lawrence Berkeley National Laboratory and a professor at the University of California, Berkeley, where she served as head of the Division of Biochemistry, Biophysics and Structural Biology of the Department of Molecular and Cell Biology (2015–2020). She is a Howard Hughes Medical Institute investigator.

<span class="mw-page-title-main">Roger D. Kornberg</span> American biochemist and professor of structural biology

Roger David Kornberg is an American biochemist and professor of structural biology at Stanford University School of Medicine. Kornberg was awarded the Nobel Prize in Chemistry in 2006 for his studies of the process by which genetic information from DNA is copied to RNA, "the molecular basis of eukaryotic transcription."

Richard D. Wood is an American molecular biologist specializing in research on DNA repair and mutation. He is known for pioneering studies on nucleotide excision repair (NER), particularly for reconstituting the minimum set of proteins involved in this process, identifying proliferating cell nuclear antigen (PCNA) as part of the NER complex and identifying mammalian repair polymerases.

<span class="mw-page-title-main">Eukaryotic transcription</span> Transcription is heterocatalytic function of DNA

Eukaryotic transcription is the elaborate process that eukaryotic cells use to copy genetic information stored in DNA into units of transportable complementary RNA replica. Gene transcription occurs in both eukaryotic and prokaryotic cells. Unlike prokaryotic RNA polymerase that initiates the transcription of all different types of RNA, RNA polymerase in eukaryotes comes in three variations, each translating a different type of gene. A eukaryotic cell has a nucleus that separates the processes of transcription and translation. Eukaryotic transcription occurs within the nucleus where DNA is packaged into nucleosomes and higher order chromatin structures. The complexity of the eukaryotic genome necessitates a great variety and complexity of gene expression control.

<span class="mw-page-title-main">Replication protein A1</span> Protein-coding gene in the species Homo sapiens

Replication protein A 70 kDa DNA-binding subunit is a protein that in humans is encoded by the RPA1 gene.

<span class="mw-page-title-main">MXD1</span> Protein-coding gene in the species Homo sapiens

MAD protein is a protein that in humans is encoded by the MXD1 gene.

The gal operon is a prokaryotic operon, which encodes enzymes necessary for galactose metabolism. Repression of gene expression for this operon works via binding of repressor molecules to two operators. These repressors dimerize, creating a loop in the DNA. The loop as well as hindrance from the external operator prevent RNA polymerase from binding to the promoter, and thus prevent transcription. Additionally, since the metabolism of galactose in the cell is involved in both anabolic and catabolic pathways, a novel regulatory system using two promoters for differential repression has been identified and characterized within the context of the gal operon.

RNA polymerase IV is an enzyme that synthesizes small interfering RNA (siRNA) in plants, which silence gene expression. RNAP IV belongs to a family of enzymes that catalyze the process of transcription known as RNA Polymerases, which synthesize RNA from DNA templates. Discovered via phylogenetic studies of land plants, genes of RNAP IV are thought to have resulted from multistep evolution processes that occurred in RNA Polymerase II phylogenies. Such an evolutionary pathway is supported by the fact that RNAP IV is composed of 12 protein subunits that are either similar or identical to RNA polymerase II, and is specific to plant genomes. Via its synthesis of siRNA, RNAP IV is involved in regulation of heterochromatin formation in a process known as RNA directed DNA Methylation (RdDM).

Mutation Frequency Decline (mfd) is the gene which encodes the protein Mfd. Mfd functions in transcription-coupled repair to remove a stalled RNA polymerase that has encountered DNA damage and is unable to continue translocating.

Lorena Beese is a James B. Duke Professor of Biochemistry and Duke Cancer Institute Member. Her research involves structural mechanisms underlying DNA replication and repair, neurodegenerative diseases, cancer, and microbial pathogenesis; X-ray crystallography and cryo-electron microscopy; structure-based drug design; protein-protein and protein-nucleic acid interactions, enzyme mechanisms, chemical biology, protein structure and function.

<span class="mw-page-title-main">Replication protein A2</span> Protein-coding gene in the species Homo sapiens

Replication protein A 32 kDa subunit is a protein that in humans is encoded by the RPA2 gene.

<span class="mw-page-title-main">Replication protein A3</span> Protein-coding gene in the species Homo sapiens

Replication protein A 14 kDa subunit is a protein that in humans is encoded by the RPA3 gene.

<span class="mw-page-title-main">Michael E. O'Donnell</span> American biochemist

Michael E. O’ Donnell is an American biochemist and a professor at the Rockefeller University specializing in the field of DNA replication.

<i>Ground squirrel hepatitis virus</i> Species of virus

Ground squirrel hepatitis virus, abbreviated GSHV, is a partially double-stranded DNA virus that is closely related to human Hepatitis B virus (HBV) and Woodchuck hepatitis virus (WHV). It is a member of the family of viruses Hepadnaviridae and the genus Orthohepadnavirus. Like the other members of its family, GSHV has high degree of species and tissue specificity. It was discovered in Beechey ground squirrels, Spermophilus beecheyi, but also infects Arctic ground squirrels, Spermophilus parryi. Commonalities between GSHV and HBV include morphology, DNA polymerase activity in genome repair, cross-reacting viral antigens, and the resulting persistent infection with viral antigen in the blood (antigenemia). As a result, GSHV is used as an experimental model for HBV.

References

  1. ↑ "Order of Canada appointees - June 2022". 21 June 2022. Retrieved 2022-06-29.
  2. ↑ "Order of Canada". archive.gg.ca. Retrieved 2019-07-12.
  3. ↑ Edwards, A. M.; Darst, S. A.; Feaver, W. J.; Thompson, N. E.; Burgess, R. R.; Kornberg, R. D. (March 1990). "Purification and lipid-layer crystallization of yeast RNA polymerase II". Proceedings of the National Academy of Sciences of the United States of America. 87 (6): 2122–2126. Bibcode:1990PNAS...87.2122E. doi: 10.1073/pnas.87.6.2122 . ISSN   0027-8424. PMC   53638 . PMID   2179949.
  4. ↑ Darst, S. A.; Edwards, A. M.; Kubalek, E. W.; Kornberg, R. D. (1991-07-12). "Three-dimensional structure of yeast RNA polymerase II at 16 A resolution". Cell. 66 (1): 121–128. doi:10.1016/0092-8674(91)90144-n. ISSN   0092-8674. PMID   2070414. S2CID   234272.
  5. ↑ Darst, S. A.; Kubalek, E. W.; Edwards, A. M.; Kornberg, R. D. (1991-09-05). "Two-dimensional and epitaxial crystallization of a mutant form of yeast RNA polymerase II". Journal of Molecular Biology. 221 (1): 347–357. doi:10.1016/0022-2836(91)80223-h. ISSN   0022-2836. PMID   1920413.
  6. ↑ Cramer, P.; Bushnell, D. A.; Fu, J.; Gnatt, A. L.; Maier-Davis, B.; Thompson, N. E.; Burgess, R. R.; Edwards, A. M.; David, P. R. (2000-04-28). "Architecture of RNA polymerase II and implications for the transcription mechanism". Science. 288 (5466): 640–649. Bibcode:2000Sci...288..640C. doi:10.1126/science.288.5466.640. hdl: 11858/00-001M-0000-0015-872F-3 . ISSN   0036-8075. PMID   10784442.
  7. ↑ Barwell, J. A.; Bochkarev, A.; Pfuetzner, R. A.; Tong, H.; Yang, D. S.; Frappier, L.; Edwards, A. M. (1995-09-01). "Overexpression, purification, and crystallization of the DNA binding and dimerization domains of the Epstein-Barr virus nuclear antigen 1". The Journal of Biological Chemistry. 270 (35): 20556–20559. doi: 10.1074/jbc.270.35.20556 . ISSN   0021-9258. PMID   7657632.
  8. ↑ Bochkarev, A.; Barwell, J. A.; Pfuetzner, R. A.; Furey, W.; Edwards, A. M.; Frappier, L. (1995-10-06). "Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein EBNA 1". Cell. 83 (1): 39–46. doi: 10.1016/0092-8674(95)90232-5 . ISSN   0092-8674. PMID   7553871. S2CID   38819630.
  9. ↑ Bochkarev, A.; Barwell, J. A.; Pfuetzner, R. A.; Bochkareva, E.; Frappier, L.; Edwards, A. M. (1996-03-08). "Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA". Cell. 84 (5): 791–800. doi: 10.1016/s0092-8674(00)81056-9 . ISSN   0092-8674. PMID   8625416. S2CID   10555528.
  10. ↑ Bochkarev, A.; Pfuetzner, R. A.; Edwards, A. M.; Frappier, L. (1997-01-09). "Structure of the single-stranded-DNA-binding domain of replication protein A bound to DNA". Nature. 385 (6612): 176–181. Bibcode:1997Natur.385..176B. doi:10.1038/385176a0. ISSN   0028-0836. PMID   8990123. S2CID   4288187.
  11. ↑ Christendat, D.; Yee, A.; Dharamsi, A.; Kluger, Y.; Savchenko, A.; Cort, J. R.; Booth, V.; Mackereth, C. D.; Saridakis, V. (October 2000). "Structural proteomics of an archaeon". Nature Structural Biology. 7 (10): 903–909. doi:10.1038/82823. ISSN   1072-8368. PMID   11017201. S2CID   389188.
  12. ↑ Vedadi, Masoud; Niesen, Frank H.; Allali-Hassani, Abdellah; Fedorov, Oleg Y.; Finerty, Patrick J.; Wasney, Gregory A.; Yeung, Ron; Arrowsmith, Cheryl; Ball, Linda J. (2006-10-24). "Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination". Proceedings of the National Academy of Sciences of the United States of America. 103 (43): 15835–15840. Bibcode:2006PNAS..10315835V. doi: 10.1073/pnas.0605224103 . ISSN   0027-8424. PMC   1595307 . PMID   17035505.
  13. ↑ Dong, Aiping; Xu, Xiaohui; Edwards, Aled M.; Midwest Center for Structural Genomics; Structural Genomics Consortium; Chang, Changsoo; Chruszcz, Maksymilian; Cuff, Marianne; Cymborowski, Marcin (December 2007). "In situ proteolysis for protein crystallization and structure determination". Nature Methods. 4 (12): 1019–1021. doi:10.1038/nmeth1118. ISSN   1548-7105. PMC   3366506 . PMID   17982461.
  14. ↑ Horner, Michael A.; Pardee, Keith; Liu, Suya; King-Jones, Kirst; Lajoie, Gilles; Edwards, Aled; Krause, Henry M.; Thummel, Carl S. (2009-12-01). "The Drosophila DHR96 nuclear receptor binds cholesterol and regulates cholesterol homeostasis". Genes & Development. 23 (23): 2711–2716. doi:10.1101/gad.1833609. ISSN   1549-5477. PMC   2788327 . PMID   19952106.
  15. ↑ Reinking, Jeff; Lam, Mandy M. S.; Pardee, Keith; Sampson, Heidi M.; Liu, Suya; Yang, Ping; Williams, Shawn; White, Wendy; Lajoie, Gilles (2005-07-29). "The Drosophila nuclear receptor e75 contains heme and is gas responsive". Cell. 122 (2): 195–207. doi: 10.1016/j.cell.2005.07.005 . ISSN   0092-8674. PMID   16051145. S2CID   1018360.
  16. ↑ Lunin, Vladimir V.; Dobrovetsky, Elena; Khutoreskaya, Galina; Zhang, Rongguang; Joachimiak, Andrzej; Doyle, Declan A.; Bochkarev, Alexey; Maguire, Michael E.; Edwards, Aled M. (2006-04-06). "Crystal structure of the CorA Mg2+ transporter". Nature. 440 (7085): 833–837. Bibcode:2006Natur.440..833L. doi:10.1038/nature04642. ISSN   1476-4687. PMC   3836678 . PMID   16598263.
  17. ↑ "RCDS PDB Search".
  18. ↑ Morgan, Maxwell Robert; Roberts, Owen Gwilym; Edwards, Aled Morgan (2018). "Ideation and implementation of an open science drug discovery business model - M4K Pharma". Wellcome Open Research. 3: 154. doi: 10.12688/wellcomeopenres.14947.1 . ISSN   2398-502X. PMC   6346698 . PMID   30705971.
  19. ↑ Jones, Molly Morgan; Castle-Clarke, Sophie; Brooker, Daniel; Nason, Edward; Huzair, Farah; Chataway, Joanna (2014-12-30). "The Structural Genomics Consortium: A Knowledge Platform for Drug Discovery: A Summary". Rand Health Quarterly. 4 (3): 19. ISSN   2162-8254. PMC   5396214 . PMID   28560088.
  20. ↑ "MNI Open Research: bringing a new level of transparency to neurological research". The Neuro. Retrieved 2019-07-12.
  21. ↑ Edwards, Aled; Morgan, Max; Al Chawaf, Arij; Andrusiak, Kerry; Charney, Rachel; Cynader, Zarya; ElDessouki, Ahmed; Lee, Yunjeong; Moeser, Andrew (May 31, 2017). "A trust approach for sharing research reagents". Science Translational Medicine. 9 (392): eaai9055. doi: 10.1126/scitranslmed.aai9055 . ISSN   1946-6242. PMID   28566431.
  22. ↑ "Aled Edwards". Ashoka | Everyone a Changemaker. Retrieved 2019-07-12.
  23. ↑ Edwards, Aled M.; Isserlin, Ruth; Bader, Gary D.; Frye, Stephen V.; Willson, Timothy M.; Yu, Frank H. (2011-02-10). "Too many roads not taken". Nature. 470 (7333): 163–165. arXiv: 1102.0448 . Bibcode:2011Natur.470..163E. doi:10.1038/470163a. ISSN   1476-4687. PMID   21307913. S2CID   4429387.
  24. ↑ "Illuminating the Druggable Genome | NIH Common Fund". commonfund.nih.gov. 9 July 2013. Retrieved 2019-07-12.
  25. ↑ Zimmer, Carl (2018-09-18). "Why Your DNA Is Still Uncharted Territory". The New York Times. ISSN   0362-4331 . Retrieved 2019-07-12.
  26. ↑ Arrowsmith, Cheryl H.; Audia, James E.; Austin, Christopher; Baell, Jonathan; Bennett, Jonathan; Blagg, Julian; Bountra, Chas; Brennan, Paul E.; Brown, Peter J. (August 2015). "The promise and peril of chemical probes". Nature Chemical Biology. 11 (8): 536–541. doi:10.1038/nchembio.1867. ISSN   1552-4469. PMC   4706458 . PMID   26196764.
  27. ↑ General, Office of the Secretary to the Governor (2009-07-01). "Governor General announces 60 new appointments to the Order of Canada". The Governor General of Canada. Retrieved 2019-07-12.
  28. ↑ "Dr Owain Edwards". people.csiro.au. Retrieved 2023-09-05.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.